We also demonstrated that both GLI1 and one of its transcriptional targets, NBS1, negatively correlate with CRC patient 5-year survival, driving chemotherapeutic resistance by overcoming FOLFOX induced DNA damage (standard of care treatment). The gene discussed is GLI1; the disease is colorectal carcinoma.